(“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. . TH | March 7, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. W. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Headquarters. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. L. MONTREAL, Oct. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Stockhouse. 81 million for the quarter. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. Share your ideas and get valuable. GUD | Complete Knight Therapeutics Inc. $30. TH1902 is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology™. Senior Director, Investor Relations. com uses cookies on this site. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. FAQ – Émetteurs inscrits NOUVEAU. 17. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. MONTREAL, Oct. The company had revenue of $20. Cookies are used to offer you a better browsing experience and to analyze our traffic. See a list of the most recent Stock Forum posts on Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. . By continuing to use our. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Clinical-stage pharmaceutical company Theralase Technologies Inc. 74M. The reported ($0. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. Cookies are used to offer you a better browsing. com. By continuing to use our service, you agree to our use of cookies. Company Description: Theratechnologies is pepped up on peptides. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. 00%. Stockhouse. Thank you. stockhouse. ET. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Theratechnologies’ R&D staff is bearing the brunt of. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. (TH. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. Cookies are used to offer you a better browsing experience and to analyze our traffic. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. “This is yet another major achievement for our oncology program. MONTREAL, Nov. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. We also use them to share usage information with our partners. Message Board Total Posts: 4. com uses cookies on this site. MONTREAL, Nov. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. 4% from the stock's current price. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. 35 as of 10:41 a. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. Theratechnologies . Company Participants. We currently market prescription products for people with. Cookies are used to offer you a better browsing experience and to analyze our traffic. Further. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. Who is Theratechnologies. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. is a pharmaceutical company. com uses cookies on this site. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. MONTREAL, Nov. Track Theratechnologies Inc. With the company starting 2023 with 8,725 employees, that’s an 11. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. We also use them to share usage information with our partners. By continuing to use our service, you agree to our use of cookies. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. S. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. (TH. Further. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock news by MarketWatch. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. m. 9 million and US. - 2023 Q3 positive adjusted EBITDA to be achieved. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. ET. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. Stockhouse. Stockhouse. Browse posts by Sector and Subsector. OTCQX – this is the premium tier of OTC stocks. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies, Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 89 52. Herein, we report. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. Cookies are used to offer you a better browsing experience and to analyze our traffic. Find the latest Theratechnologies Inc. home message. com uses cookies on this site. - Issued and outstanding common shares to be consolidated on the basis of 1 post. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. stock news by MarketWatch. 25. com uses cookies on this site. Phone Number (514) 336-7800. Type: Company - Public (TH) Revenue: $5 to $25 million (USD) Biotech & Pharmaceuticals. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. Montréal, Québec, Canada . This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. MONTREAL, Dec. View real-time stock prices and stock quotes for a full financial overview. 10% least volatile stocks in CA Market. Biopharmaceutical company Theratechnologies Inc. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. View real-time stock prices and stock quotes for a full financial overview. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. (THTX) Stock Price, Quote & News - Stock Analysis -20. (2013-04-03 | TSX:TH) Theratechnologies Inc. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. Theratechnologies Inc. MONTREAL, Aug. Stockhouse. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. sBLA for F8 formulation of tesamorelin submitted to FDA. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 521. Theratechnologies Inc. 33. MONTREAL, Sept. View analysts price targets for THTX. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 68 to a day high of $1. Denis Boucher. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. 63. THERATECHNOLOGIES INC. A high-level overview of Theratechnologies Inc. 82 million. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. Pour les émetteurs. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. VANCOUVER, British Columbia, Nov. Follow. - Q3 2022 Consolidated. Proceeds to Be Used to Redeem All of the Outstanding 5. stock news by MarketWatch. Stockhouse. Theratechnologies's earnings have been declining at an average annual rate of -35. 00, suggesting a possible upside of. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. T. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. For investor inquiries: Leah Gibson. -4. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. com uses cookies on this site. European Headquarters. European Headquarters. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. -based clinical sites participating in the conduct of the Phase. THERATECHNOLOGIES INC. Volume has increased on the last day along with the price, which is a. MONTREAL, Dec. MONTREAL, Feb. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. FY2023 revenue guidance range set between $90 million and $95 million. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Microsoft to invest $500M in Quebec AI economy. Their average twelve-month price target is $36. 08 (+6. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. 38. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. Stockhouse. 06 million, an increase of 14. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. 66% compared to the previous year's 69. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. FDA for its IV push form of administration of Trogarzo. 04) earnings per share (EPS) for the quarter. Gary Littlejohn Stockhouse. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 26 +15. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. com uses cookies on this site. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. The FDA granted fast track designation to TH1902 as a single agent for. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. acts as investment manager. . These companies provide a lot of detail to the OTC Markets Group including audited financials. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. THTX | Complete Theratechnologies Inc. Stockhouse. By continuing to use our service, you agree to our use of cookies. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. When this page refreshes you will be logged in with the new address. Cookies are used to offer you a better browsing experience and to analyze our traffic. Investor Relations. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. com uses cookies on this site. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. We also use them to share usage information with our partners. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. 75. Stockhouse. 1-438. T. The Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies Inc. licensed the product from TaiMed Biologics, Inc. . Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 4. Marsolais will present at the H. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Stockhouse. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. 9 million and US$19. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. Website. Cookies are used to offer you a better browsing experience and to. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. Theratechnologies reduces R&D head count to compensate for sales setback. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. : 001-35203 Mr. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. 00. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - Q3 2022 Consolidated Revenue Growth of 17% to $20. Learn why it. Katana shareholders will. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Q4 2022 consolidated revenue growth of 14. FY2022 revenue. com. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Wainwright NASH Investor Conference. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. 's motion for leave to commence. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further. - Cash, bonds and money market funds of US$22. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Theratechnologies layoffs. T. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Contact Email communications@theratech. By continuing to use our service, you agree to our use of cookies. 33 +0. 124. The Company currently commercializes two products in the field of HIV.